Skip to Content
Merck
  • 68Ga-chloride PET reveals human pancreatic adenocarcinoma xenografts in rats--comparison with FDG.

68Ga-chloride PET reveals human pancreatic adenocarcinoma xenografts in rats--comparison with FDG.

Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging (2009-10-03)
Tiina Ujula, Satu Salomäki, Anu Autio, Pauliina Luoto, Tuula Tolvanen, Pertti Lehikoinen, Tapio Viljanen, Hannu Sipilä, Pirkko Härkönen, Anne Roivainen
ABSTRACT

The aim of the study was to compare (68)Ga-chloride with 2-[(18)F]fluoro-2-deoxy-D: -glucose (FDG) for the imaging of pancreatic xenografts. Rats with subcutaneous human pancreatic adenocarcinoma xenografts were evaluated in vivo by dynamic positron emission tomography (PET) and ex vivo by measuring radioactivity of excised tissues and by digital autoradiography of tumor cryosections. Both tracers were capable of delineating all subcutaneous tumors from surrounding tissues by PET. The standardized uptake values of tumors by PET were 0.9 +/- 0.3 (mean +/- SD) for (68)Ga-chloride (n = 13) and 1.8 +/- 1.2 for FDG (n = 11). Ex vivo studies showed tumor-to-muscle ratio of 4.0 +/- 0.3 for (68)Ga-chloride (n = 4) and 7.9 +/- 3.2 for FDG (n = 4). (68)Ga-chloride delineated subcutaneously implanted pancreatic adenocarcinoma xenografts by PET, but the uptake was lower than FDG. Further studies to clarify the value of (68)Ga-chloride for PET imaging of tumors are warranted.